Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents

被引:36
|
作者
Lu, Junxuan [1 ]
Kim, Sung-Hoon
Jiang, Cheng
Lee, HyoJeong
Guo, Junming
机构
[1] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA
[2] Kyung Hee Univ, Coll Oriental Med, Seoul 131701, South Korea
关键词
anti-androgen; prostate cancer; chemo-prevention; pyranocoumarin; herbal medicine;
D O I
10.1111/j.1745-7254.2007.00683.x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Androgen and androgen receptor (AR) signaling are crucial for the genesis of prostate cancer (PCa), which can often develop into androgen-ligand-independent diseases that are lethal to the patients. Recent studies show that even these hormone-refractory PCa require ligand-independent AR signaling for survival. As current chemotherapy is largely ineffective for PCa and has serious toxic side-effects, we have initiated a collaborative effort to identify and develop novel, safe and naturally occurring agents that target AR signaling from Oriental medicinal herbs for the chemoprevention and treatment of PCa. We highlight our discovery of decursin from an Oriental formula containing Korean Angelica gigas Nakai (Dang Gui) root as a novel anti-androgen/AR agent. We have identified the following mechanisms to account for the specific anti-AR actions: rapid block of AR nuclear translocation, inhibition of binding of 5 alpha-dihydrotestesterone to AR and increased proteasomal degradation of AR protein. Furthermore, decursin lacks the agonist activity of the "pure" anti-androgen bicalutamide and is more potent than bicalutamide in inducing PCa apoptosis. Structure-activity analyses reveal a critical requirement of the side-chain on decursin or its structural isomer decursinol angelate for anti-AR, cell cycle arrest and proapoptotic activities. This work demonstrates the feasibility of using activity-guided fractionation in cell culture assays combined with mechanistic studies to identify novel anti-androgen/AR agents from complex herbal mixtures.
引用
收藏
页码:1365 / 1372
页数:8
相关论文
共 50 条
  • [1] Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents
    HyoJeong LEE
    [J]. Acta Pharmacologica Sinica, 2007, (09) : 1365 - 1372
  • [2] Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents
    Junxuan Lü
    Sung-Hoon Kim
    Cheng Jiang
    HyoJeong Lee
    Junming Guo
    [J]. Acta Pharmacologica Sinica, 2007, 28 : 1365 - 1372
  • [3] Potent anti-androgen and prostate cancer preventive activities of an oriental herbal formula.
    Jiang, C
    Lee, HJ
    Guo, JM
    Li, GX
    Malewicz, B
    Zhao, Y
    Lee, EO
    Lee, HJ
    Lee, JH
    Kim, MS
    Kim, SH
    Lü, JX
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2720S - 2720S
  • [4] Anti-androgen monotherapy for metastatic prostate cancer
    Attard, Gerhardt
    [J]. LANCET ONCOLOGY, 2014, 15 (06): : 543 - 544
  • [5] Real world utilization and disparities in outcome in the use of novel anti-androgen agents for metastatic prostate cancer
    Hirani, Samina
    Durojaiye, Ashimiyu
    He, Jian
    Sabo, Roy T.
    Paul, Asit K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
    Zhang, Haozhe
    Zhou, Yi
    Xing, Zengzhen
    Sah, Rajiv Kumar
    Hu, Junqi
    Hu, Hailiang
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [7] Anti-Androgen Therapies for Prostate Cancer: A Focused Review
    Ammannagari, Nischala
    George, Saby
    [J]. AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (02) : 15 - 19
  • [8] Prostate cancer risk after anti-androgen treatment for priapism
    Tabitha Goetz
    Arthur L. Burnett
    [J]. International Urology and Nephrology, 2014, 46 : 757 - 760
  • [9] Prostate cancer risk after anti-androgen treatment for priapism
    Goetz, Tabitha
    Burnett, Arthur L.
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (04) : 757 - 760
  • [10] Third generation anti-androgen therapy of advanced prostate cancer
    Ohlmann, C. -H.
    Kamradt, J.
    Stoeckle, M.
    [J]. UROLOGE, 2012, 51 (04): : 522 - 526